Timo Behlendorf

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy

Karin Jordan, Iris Kinitz, Wieland Voigt et al. · European Journal of Cancer · 2009 · 50 citations

Medicine, Pharmacology, Pharmacotherapy +14

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination

Karin Jordan, Franziska Jahn, Patrick Jahn et al. · Bone Marrow Transplantation · 2010 · 34 citations

Medicine, Oncology, Pharmacology +17

2-(4-(tetrahydro-2<i>H</i>-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): A Novel Platinum Compound that Overcomes Cisplatin Resistance and Induces Apoptosis by Mechanisms Different from that of Cisplatin

Andrea Dietrich, Thomas Mueller, Reinhard Paschke et al. · Journal of Medicinal Chemistry · 2008 · 24 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis

Franziska Jahn, Karin Jordan, Timo Behlendorf et al. · Oncology · 2015 · 18 citations

Medicine, Oncology, Pharmacology +13

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial

Petra Langerbeins, Sandra Robrecht, Pascal Nieper et al. · Journal of Clinical Oncology · 2024 · 15 citations

Medicine, Oncology, Pharmacotherapy +13